Neuroendocrine carcinoma of the head and neck

A 20-year case series

Ryan Meacham, Laura Matrka, Enver Ozer, H. Gulcin Ozer, Paul Wakely, Manisha Shah

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Neuroendocrine carcinoma (NEC) can be an aggressive disease with locoregional and distant metastasis. We present this article (1) to highlight the typical presentation of NEC in head and neck primary sites such as the parotid gland, paranasal sinuses, and supraglottis and (2) to discuss the prognosis of these tumors based on their histologic subtype and stage. We base our comments on the findings of our retrospective review of the cases of 16 adults-10 men and 6 women, aged 43 to 88 years (mean: 65.8)-who had been diagnosed with pathologically confirmed NEC of the head and neck. Analysis of subtypes revealed that 11 of these patients (68.8%) had presented with poorly differentiated NEC, 4 (25.0%) with moderately differentiated NEC, and 1 (6.3%) with well-differentiated NEC. The most common primary sites were the salivary glands (n = 5; 31.3%), paranasal sinuses (n = 4, 25.0%), and larynx (n = 4). There was no statistically significant difference in survival at 24 months between the patients with moderately differentiated NEC and those with poorly differentiated NEC (37.5 vs. 35.4%; p = 0.86); at the end of the study period, the patient with well-differentiated NEC was still living, 129 months after diagnosis. Taken together, patients with stage I, II, and III disease had a combined survival of 77.8% at 12 months, which was significantly higher (p = 0.023) than the 57.1% survival at 12 months for patients with stage IV disease.

Original languageEnglish (US)
JournalEar, Nose and Throat Journal
Volume91
Issue number3
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Neuroendocrine Carcinoma
Neck
Head
Paranasal Sinuses
Survival
Parotid Gland
Larynx
Salivary Glands
Neoplasm Metastasis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Meacham, R., Matrka, L., Ozer, E., Ozer, H. G., Wakely, P., & Shah, M. (2012). Neuroendocrine carcinoma of the head and neck: A 20-year case series. Ear, Nose and Throat Journal, 91(3).

Neuroendocrine carcinoma of the head and neck : A 20-year case series. / Meacham, Ryan; Matrka, Laura; Ozer, Enver; Ozer, H. Gulcin; Wakely, Paul; Shah, Manisha.

In: Ear, Nose and Throat Journal, Vol. 91, No. 3, 03.2012.

Research output: Contribution to journalArticle

Meacham, R, Matrka, L, Ozer, E, Ozer, HG, Wakely, P & Shah, M 2012, 'Neuroendocrine carcinoma of the head and neck: A 20-year case series', Ear, Nose and Throat Journal, vol. 91, no. 3.
Meacham R, Matrka L, Ozer E, Ozer HG, Wakely P, Shah M. Neuroendocrine carcinoma of the head and neck: A 20-year case series. Ear, Nose and Throat Journal. 2012 Mar;91(3).
Meacham, Ryan ; Matrka, Laura ; Ozer, Enver ; Ozer, H. Gulcin ; Wakely, Paul ; Shah, Manisha. / Neuroendocrine carcinoma of the head and neck : A 20-year case series. In: Ear, Nose and Throat Journal. 2012 ; Vol. 91, No. 3.
@article{aea788d1e96743db8dab9a13f1aa0a35,
title = "Neuroendocrine carcinoma of the head and neck: A 20-year case series",
abstract = "Neuroendocrine carcinoma (NEC) can be an aggressive disease with locoregional and distant metastasis. We present this article (1) to highlight the typical presentation of NEC in head and neck primary sites such as the parotid gland, paranasal sinuses, and supraglottis and (2) to discuss the prognosis of these tumors based on their histologic subtype and stage. We base our comments on the findings of our retrospective review of the cases of 16 adults-10 men and 6 women, aged 43 to 88 years (mean: 65.8)-who had been diagnosed with pathologically confirmed NEC of the head and neck. Analysis of subtypes revealed that 11 of these patients (68.8{\%}) had presented with poorly differentiated NEC, 4 (25.0{\%}) with moderately differentiated NEC, and 1 (6.3{\%}) with well-differentiated NEC. The most common primary sites were the salivary glands (n = 5; 31.3{\%}), paranasal sinuses (n = 4, 25.0{\%}), and larynx (n = 4). There was no statistically significant difference in survival at 24 months between the patients with moderately differentiated NEC and those with poorly differentiated NEC (37.5 vs. 35.4{\%}; p = 0.86); at the end of the study period, the patient with well-differentiated NEC was still living, 129 months after diagnosis. Taken together, patients with stage I, II, and III disease had a combined survival of 77.8{\%} at 12 months, which was significantly higher (p = 0.023) than the 57.1{\%} survival at 12 months for patients with stage IV disease.",
author = "Ryan Meacham and Laura Matrka and Enver Ozer and Ozer, {H. Gulcin} and Paul Wakely and Manisha Shah",
year = "2012",
month = "3",
language = "English (US)",
volume = "91",
journal = "Ear, Nose and Throat Journal",
issn = "0145-5613",
publisher = "Medquest Communications LLC",
number = "3",

}

TY - JOUR

T1 - Neuroendocrine carcinoma of the head and neck

T2 - A 20-year case series

AU - Meacham, Ryan

AU - Matrka, Laura

AU - Ozer, Enver

AU - Ozer, H. Gulcin

AU - Wakely, Paul

AU - Shah, Manisha

PY - 2012/3

Y1 - 2012/3

N2 - Neuroendocrine carcinoma (NEC) can be an aggressive disease with locoregional and distant metastasis. We present this article (1) to highlight the typical presentation of NEC in head and neck primary sites such as the parotid gland, paranasal sinuses, and supraglottis and (2) to discuss the prognosis of these tumors based on their histologic subtype and stage. We base our comments on the findings of our retrospective review of the cases of 16 adults-10 men and 6 women, aged 43 to 88 years (mean: 65.8)-who had been diagnosed with pathologically confirmed NEC of the head and neck. Analysis of subtypes revealed that 11 of these patients (68.8%) had presented with poorly differentiated NEC, 4 (25.0%) with moderately differentiated NEC, and 1 (6.3%) with well-differentiated NEC. The most common primary sites were the salivary glands (n = 5; 31.3%), paranasal sinuses (n = 4, 25.0%), and larynx (n = 4). There was no statistically significant difference in survival at 24 months between the patients with moderately differentiated NEC and those with poorly differentiated NEC (37.5 vs. 35.4%; p = 0.86); at the end of the study period, the patient with well-differentiated NEC was still living, 129 months after diagnosis. Taken together, patients with stage I, II, and III disease had a combined survival of 77.8% at 12 months, which was significantly higher (p = 0.023) than the 57.1% survival at 12 months for patients with stage IV disease.

AB - Neuroendocrine carcinoma (NEC) can be an aggressive disease with locoregional and distant metastasis. We present this article (1) to highlight the typical presentation of NEC in head and neck primary sites such as the parotid gland, paranasal sinuses, and supraglottis and (2) to discuss the prognosis of these tumors based on their histologic subtype and stage. We base our comments on the findings of our retrospective review of the cases of 16 adults-10 men and 6 women, aged 43 to 88 years (mean: 65.8)-who had been diagnosed with pathologically confirmed NEC of the head and neck. Analysis of subtypes revealed that 11 of these patients (68.8%) had presented with poorly differentiated NEC, 4 (25.0%) with moderately differentiated NEC, and 1 (6.3%) with well-differentiated NEC. The most common primary sites were the salivary glands (n = 5; 31.3%), paranasal sinuses (n = 4, 25.0%), and larynx (n = 4). There was no statistically significant difference in survival at 24 months between the patients with moderately differentiated NEC and those with poorly differentiated NEC (37.5 vs. 35.4%; p = 0.86); at the end of the study period, the patient with well-differentiated NEC was still living, 129 months after diagnosis. Taken together, patients with stage I, II, and III disease had a combined survival of 77.8% at 12 months, which was significantly higher (p = 0.023) than the 57.1% survival at 12 months for patients with stage IV disease.

UR - http://www.scopus.com/inward/record.url?scp=84861507825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861507825&partnerID=8YFLogxK

M3 - Article

VL - 91

JO - Ear, Nose and Throat Journal

JF - Ear, Nose and Throat Journal

SN - 0145-5613

IS - 3

ER -